Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients

The recurrence rates of Hepatocellular carcinoma (HCC) are high, necessitating novel and effective adjuvant therapies. Therefore, we conducted a phase II study of glypican-3 (GPC3) peptide vaccine as an adjuvant therapy for HCC patients. Forty-one patients with initial HCC who had undergone surgery...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncoimmunology
Prif Awduron: Sawada, Yu, Yoshikawa, Toshiaki, Ofuji, Kazuya, Yoshimura, Mayuko, Tsuchiya, Nobuhiro, Takahashi, Mari, Nobuoka, Daisuke, Gotohda, Naoto, Takahashi, Shinichiro, Kato, Yuichiro, Konishi, Masaru, Kinoshita, Taira, Ikeda, Masafumi, Nakachi, Kohei, Yamazaki, Naoya, Mizuno, Shoichi, Takayama, Tadatoshi, Yamao, Kenji, Uesaka, Katsuhiko, Furuse, Junji, Endo, Itaru, Nakatsura, Tetsuya
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Taylor & Francis 2016
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4910752/
https://ncbi.nlm.nih.gov/pubmed/27467945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1129483
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg